Product overview

Name PKC-412
Alternative names CGP 41251; Midostaurin; 4'-N-benzoylstaurosporine; PKC412
Purity >96%
Description Broad spectrum protein kinase inhibitor
Write Your Own Review
You're reviewing:PKC-412
Rate this item:

Biological Data

Biological description Broad spectrum protein kinase inhibitor. Inhibits PKC (isoforms α, β and γ), Syk, FLK-1, PKA, c-kit, Akt, FLT3, VEGFR1, VEGFR2, EGFR and c-src. Also selectively blocks TNF-α production. Displays antitumor, antiproliferative and pro-apoptotic properties.

Solubility & Handling

Solubility overview Soluble in DMSO (15mg/ml) or MDC (10mg/ml)
Storage of solutions Prepare and use solutions on the same day if possible. Store solutions at -20°C for up to one month if storage is required. Equilibrate to RT and ensure the solution is precipitate free before use.
Shipping Conditions Stable for ambient temperature shipping. Follow storage instructions on receipt.
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

Calculators

Molarity

=
x
x
More Info

Dilution

x
=
x
More Info

Chemical Data

Purity >96%
Chemical name Midostaurin; 4'-N-benzoylstaurosporine
Molecular Weight 570.64
Chemical structure PKC-412  [120685-11-2] Chemical Structure
Molecular Formula C35H30N4O4
CAS Number 120685-11-2
SMILES CO[C@]1(C)[C@@H]([C@H]2O[C@]1(C)n3c4ccccc4c5c6CNC(=O)c6c7c8ccccc8n2c7c35)N(C)C(=O)c9ccccc9

References for PKC-412

References are publications that support the biological activity of the product
  • Effects of the kinase inhibitor CGP41251 (PKC 412) on lymphocyte activation and TNF-alpha production.

    Si MS et al (2005) Int Immunopharmacol 5(7-8) : 1141-9.
  • PKC412 induces apoptosis through a caspase-dependent mechanism in human keloid-derived fibroblasts.

    Nakazono-Kusaba A et al (2004) Eur J Pharmacol 497(2) : 155-60.
  • The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C.

    Tenzer A et al (2001) Cancer Res 61(22) : 8203-10.
  • PKC412--a protein kinase inhibitor with a broad therapeutic potential.

    Fabbro D et al (2000) Anticancer Drug Des 15(1) : 17-28.

4 Item(s)